Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23287623 | 0.85 | ALDH1A1 (0.44) | EPHX2 | |
| SCHEMBL23287628 | 0.80 | MAPT (0.52) | EPHX2MAPTSMN1; SMN2LMNA | |
| SCHEMBL16015039 | 0.77 | ATM (0.61) | SMN1; SMN2LMNA | |
| SCHEMBL5199840 | 0.75 | SMN1; SMN2 (0.60) | EPHX2MAPTSMN1; SMN2 | |
| SCHEMBL426570 | 0.74 | LPL (0.57) | — | |
| SCHEMBL442711 | 0.73 | CA1 (0.50) | — | |
| SCHEMBL586178 | 0.73 | LPL (0.56) | — | |
| SCHEMBL2822368 | 0.73 | POLB (0.67) | SMN1; SMN2LMNA | |
| SCHEMBL171459 | 0.73 | GAA (0.44) | MAPTLMNA | |
| SCHEMBL5222207 | 0.73 | GAA (0.59) | MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112707907-B | Purine derivative and intermediate thereof, and application of purine derivative and intermediate thereof in preparation of anti-cancer drugs | 张飞 | 2023-05-23 | — | — | CN | disclosed |
| US-20220389017-A1 | NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE | SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20210340146-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD (CN) | 2021-11-04 | — | — | US | disclosed |
| WO-2021078141-A1 | NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE | 苏州锐明新药研发有限公司 | 2021-04-29 | — | — | WO | disclosed |
| WO-2020063636-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | 苏州锐明新药研发有限公司 | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389017-A1 | NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE | PNP, ENTPD5, NTPCR | EPHX2 2704/4885MAPT 4875/4885SMN1; SMN2 3525/4885 |
| US-20210340146-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | PIK3CA, PIK3CD, PIK3R5 | EPHX2 3470/4885MAPT 4752/4885SMN1; SMN2 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.